India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

The Paris Catacombs are the City of Light's darkest tourist attraction: labyrinthine tunnels that house the remains of six ...

By day, 26-year-old Queen Tahj is a cybersecurity expert. However, it’s her passion that has gotten her national attention.

The Super Bowl 59 logo is a historic and visually striking design that stands out from previous years. Unlike past Super Bowl logos that followed a standardized template with minimal local ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the 25th anniversary of its Vashi plant. The facility is crucial for ...

Talk to many architects, and they'll likely tell you that Autodesk's software, including AutoCAD and Revit, has been ...

Called the “Plane de Lis,” the new mark is packed full of winks to the city of New Orleans and the airport itself. As the name suggests, it’s meant to evoke both an airplane and a fleur-de-lis—a stark ...

Mumbai, Vashi (Maharashtra) [India], January 31: Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited ...

ICICI Pru Regular Savings Fund (G) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-M) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-Q) 6.13 62,263 0.19 ...

Nippon India Small Cap Fund - Direct (G) 560.96 28,45,731 0.91 Nippon India Small Cap Fund - Direct (B) 560.96 28,45,731 0.91 Nippon India Small Cap Fund (B) 560.96 ...

Bonus Apr 05, 2010 Apr 06, 2010 Feb 25, 2010 Bonus Ratio: 1 share(s) for every 2 shares held Bonus Aug 30, 2006 Aug 31, 2006 Apr 28, 2006 Bonus Ratio: 1 share(s) for every 1 shares held Zydus ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value ...